Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer

EAM Heijnsdijk, A der Kinderen, EM Wever… - British journal of …, 2009 - nature.com
Background: Prostate cancer screening with prostate-specific antigen (PSA) has shown to
reduce prostate cancer mortality in the European Randomised study of Screening for …

[PDF][PDF] Lies, damn lies, and cancer statistics

P Albertsen - European urology, 2009 - Citeseer
Patients and clinicians often have difficulty translating published medical statistics into a true
understanding of the natural history of disease and the impact of treatment. This is especially …

[PDF][PDF] Dépistage du cancerde la prostate: actualité

T Tawadros, A Doerfler, C Treuthardt, V Praz, F Levi… - Rev Med Suisse, 2009 - revmed.ch
Le cancer de la prostate (CaP) est le cancer le plus fréquent chez l'homme de plus de 50
ans dans les pays occidentaux. 1 Bien que certaines formes de ce cancer puissent être …

[PDF][PDF] 1. Wat zijn de langetermijneffecten van botulinen toxine-A bij overactieve blaas? van Leeuwen PJ, Blok BFM. Urologen Vademecum. 2008 Apr; Huisartsen …

MJ Roobol, TL Tammela, S Ciatto, V Nelen… - Prostate Cancer …, 2009 - academia.edu
19. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen
in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Roobol MJ …

[PDF][PDF] Prostataspecifikt antigen

UH Stenman - i Norden, 2009 - nfkk.org
Prostataspecifikt antigen (PSA), som numera även kallas KlK3, beskrevs som en ny markör
för prostatacancer (PCa) för drygt tre decennier sedan och är i dag den mest använda och …